A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

Dangas, George; G.P. Tijssen, Jan; Wöhrle, Jochen; Søndergaard, Lars; Gilard, Martine; Möllmann, Helge; Makkar, Raj; C. Herrmann, Howard; Giustino, Gennaro; Baldus, Stephan; De Backer, Ole; H.C. Guimarães, Ana; Gullestad, Lars; Kini, Annapoorna; von Lewinski, Dirk; J. Mack, Michael; Moreno, Raúl; Schäfer, Ulrich; Seeger, Julia; Tchétché, Didier; Thomitzek, Karen; Valgimigli, Marco; Vranckx, Pascal; C. Welsh, Robert; Wildgoose, Peter; A. Volkl, Albert; Denise Zazula, Ana; van Amsterdam, R.G.M.; Mehran, Roxana; Windecker, Stephan

doi:10.1056/nejmoa1911425

Public

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

Published in New England Journal of Medicine • Nov 16, 2019

Authors:

George Dangas

Jan G.P. Tijssen

Jochen Wöhrle

Abstract

BACKGROUND: Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear. METHODS: We randomly assigned 1644 patients without an established indication for oral anticoagulation after successful TAVR to receive riv...

Subject

Rivaroxaban

Medicine

Cardiology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!